Canadian biotech industry one of the best in world, but fragile

More than half of our public biotech enterprises face a severe cash crunch: Martin

November 3, 2003

This is an edited excerpt of Paul Martin's speech he delivered to the Board of Trade of Metropolitan Montreal on Sept. 18.

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Tuesdays: Innovation & Industry Newsletter

The policies, decisions, and people working on investment and regulation in the industry and innovation realm.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy

FOLLOW THE HILL TIMES:

LICENSING

PODCAST

ALERTS

Want to make sure your whole office has the full Hill Times experience?

We have team plans available for companies, organizations, classes, Parliament Hill offices and more. Fill out this form and find out if your team is eligible for a discount.

MORE News

Two MPs rescind requests to remove Indigenous references from federal riding names

newsBY LAURA RYCKEWAERT

Is Asia being overlooked amid Carney’s European focus?

newsBY NEIL MOSS

Despite digital ad advantage, Conservative comms not cutting through Liberals’ ‘macro’ messaging

newsBY STUART BENSON

OLO exits reflect a ‘natural evolution’ from election-ready sprint to long-haul planning, say politicos

newsBY STUART BENSON

Spending to outsource legal work more than doubled in the last decade as hundreds of internal positions stayed vacant: government data

newsBY IREM KOCA